Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Hellström KE[au]:

Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response. Hellstrom KE et al. Hum Antibodies. (2017)

Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Dai M et al. Clin Cancer Res. (2015)

Tumor Regression and Cure Depends on Sustained Th1 Responses. Dai M et al. J Immunother. (2018)

Search results

Items: 1 to 50 of 379

1.

From the Hellstrom paradox toward cancer cure.

Hellstrom KE, Hellstrom I.

Prog Mol Biol Transl Sci. 2019;164:1-24. doi: 10.1016/bs.pmbts.2018.11.002. Epub 2019 Jan 14.

PMID:
31383402
2.

Ovarian carcinomas express HE4 epitopes independently of each other.

Hellstrom I, Yip YY, Darvas M, Swisher E, Hellstrom KE.

Cancer Treat Res Commun. 2019 May 24;21:100152. doi: 10.1016/j.ctarc.2019.100152. [Epub ahead of print]

PMID:
31226514
3.

Tumor Regression and Cure Depends on Sustained Th1 Responses.

Dai M, Hellstrom I, Yip YY, Sjögren HO, Hellstrom KE.

J Immunother. 2018 Oct;41(8):369-378. doi: 10.1097/CJI.0000000000000231.

4.

Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response.

Hellstrom KE, Dai M, Hellstrom I.

Hum Antibodies. 2017;25(3-4):147-153. doi: 10.3233/HAB-160309. Review.

PMID:
28085017
5.

Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.

Yu-Rice Y, Edassery SL, Urban N, Hellstrom I, Hellstrom KE, Deng Y, Li Y, Luborsky JL.

Reproduction. 2017 Mar;153(3):277-284. doi: 10.1530/REP-16-0265. Epub 2016 Dec 13.

6.

An In Vitro Model That Predicts the Therapeutic Efficacy of Immunomodulatory Antibodies.

Dai M, Yip YY, Hellstrom I, Hellstrom KE.

J Immunother. 2016 Oct;39(8):298-305. doi: 10.1097/CJI.0000000000000135.

PMID:
27488724
7.

Immune Mechanisms Are Major Players in Cancer.

Hellstrom KE, Hellstrom I.

Clin Cancer Res. 2015 Aug 15;21(16):3581-3. doi: 10.1158/1078-0432.CCR-15-0531. Epub 2015 Apr 22.

8.

Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.

Liao JB, Yip YY, Swisher EM, Agnew K, Hellstrom KE, Hellstrom I.

Gynecol Oncol. 2015 Jun;137(3):430-5. doi: 10.1016/j.ygyno.2015.03.044. Epub 2015 Apr 9.

9.

Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.

Dai M, Yip YY, Hellstrom I, Hellstrom KE.

Clin Cancer Res. 2015 Mar 1;21(5):1127-38. doi: 10.1158/1078-0432.CCR-14-1339. Epub 2014 Aug 20.

10.

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy.

Wei H, Zhao L, Hellstrom I, Hellstrom KE, Guo Y.

Oncoimmunology. 2014 Mar 28;3:e28248. eCollection 2014.

11.

Human and mouse CD137 have predominantly different binding CRDs to their respective ligands.

Yi L, Zhao Y, Wang X, Dai M, Hellström KE, Hellström I, Zhang H.

PLoS One. 2014 Jan 21;9(1):e86337. doi: 10.1371/journal.pone.0086337. eCollection 2014.

12.

Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin.

Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai M, Hellstrom I, Hellstrom KE, Guo Y.

PLoS One. 2013 Dec 19;8(12):e84927. doi: 10.1371/journal.pone.0084927. eCollection 2013.

13.

Anti-HE4 antibodies in infertile women and women with ovarian cancer.

Hellstrom I, Swisher E, Hellstrom KE, Yip YY, Agnew K, Luborsky JL.

Gynecol Oncol. 2013 Sep;130(3):629-33. doi: 10.1016/j.ygyno.2013.05.028. Epub 2013 May 28.

14.

Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.

Dai M, Wei H, Yip YY, Feng Q, He K, Popov V, Hellstrom I, Hellstrom KE.

J Immunother. 2013 May;36(4):248-57. doi: 10.1097/CJI.0b013e3182943549.

15.

Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.

Feng Q, Wei H, Morihara J, Stern J, Yu M, Kiviat N, Hellstrom I, Hellstrom KE.

Gynecol Oncol. 2012 Nov;127(2):412-9. doi: 10.1016/j.ygyno.2012.07.098. Epub 2012 Jul 22.

16.

Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

Wei H, Hellström KE, Hellström I.

Gynecol Oncol. 2012 Jun;125(3):727-33. doi: 10.1016/j.ygyno.2012.03.018. Epub 2012 Mar 16.

17.

Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma.

Wei H, Liu P, Swisher E, Yip YY, Tse JH, Agnew K, Hellström KE, Hellström I.

J Immunother. 2012 Apr;35(3):267-75. doi: 10.1097/CJI.0b013e31824d72ee.

18.

Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.

Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellström I, Hellström KE, Urban N.

Gynecol Oncol. 2012 Apr;125(1):65-9. doi: 10.1016/j.ygyno.2011.11.050. Epub 2011 Dec 7.

19.

Autoantibodies to mesothelin in infertility.

Luborsky JL, Yu Y, Edassery SL, Jaffar J, Yip YY, Liu P, Hellstrom KE, Hellstrom I.

Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1970-8. doi: 10.1158/1055-9965.EPI-11-0139. Epub 2011 Aug 16.

20.

fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.

Hellstrom I, Hellstrom KE.

Expert Opin Med Diagn. 2011 May 1;5(3):227-240.

21.

Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models.

Liu Y, Tuve S, Persson J, Beyer I, Yumul R, Li ZY, Tragoolpua K, Hellström KE, Roffler S, Lieber A.

Cancer Gene Ther. 2011 Jun;18(6):407-18. doi: 10.1038/cgt.2011.8. Epub 2011 Mar 11.

22.

Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy.

Lei C, Liu P, Chen B, Mao Y, Engelmann H, Shin Y, Jaffar J, Hellstrom I, Liu J, Hellstrom KE.

J Am Chem Soc. 2010 May 26;132(20):6906-7. doi: 10.1021/ja102414t. Erratum in: J Am Chem Soc. 2011 Sep 14;133(36):14467.

23.

Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms.

Hellstrom I, Heagerty PJ, Swisher EM, Liu P, Jaffar J, Agnew K, Hellstrom KE.

Cancer Lett. 2010 Oct 1;296(1):43-8. doi: 10.1016/j.canlet.2010.03.013. Epub 2010 Apr 8.

24.

Administration of cyclophosphamide changes the immune profile of tumor-bearing mice.

Liu P, Jaffar J, Hellstrom I, Hellstrom KE.

J Immunother. 2010 Jan;33(1):53-9. doi: 10.1097/CJI.0b013e3181b56af4.

25.

Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer.

Johnston FM, Tan MC, Tan BR Jr, Porembka MR, Brunt EM, Linehan DC, Simon PO Jr, Plambeck-Suess S, Eberlein TJ, Hellstrom KE, Hellstrom I, Hawkins WG, Goedegebuure P.

Clin Cancer Res. 2009 Nov 1;15(21):6511-8. doi: 10.1158/1078-0432.CCR-09-0565. Epub 2009 Oct 20.

26.

In situ adenovirus vaccination engages T effector cells against cancer.

Tuve S, Liu Y, Tragoolpua K, Jacobs JD, Yumul RC, Li ZY, Strauss R, Hellström KE, Disis ML, Roffler S, Lieber A.

Vaccine. 2009 Jun 24;27(31):4225-39. doi: 10.1016/j.vaccine.2009.03.074. Epub 2009 Apr 16.

27.

Inhibition of TGFbeta1 makes nonimmunogenic tumor cells effective for therapeutic vaccination.

Liu P, Jaffar J, Zhou Y, Yang Y, Hellström I, Hellström KE.

J Immunother. 2009 Apr;32(3):232-9. doi: 10.1097/CJI.0b013e318197ac86.

PMID:
19242377
28.

Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients.

Hellstrom I, Friedman E, Verch T, Yang Y, Korach J, Jaffar J, Swisher E, Zhang B, Ben-Baruch G, Tan MC, Goedegebuure P, Hellstrom KE.

Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1520-6. doi: 10.1158/1055-9965.EPI-08-0039.

29.

SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.

Hellstrom I, Hellstrom KE.

Adv Exp Med Biol. 2008;622:15-21. doi: 10.1007/978-0-387-68969-2_2. Review.

PMID:
18546615
30.

Vaccines to treat cancer--an old approach whose time has arrived.

Hellstrom KE, Hellstrom I.

J Cell Biochem. 2007 Oct 1;102(2):291-300. Review.

PMID:
17729239
31.

Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.

Yang Y, Yang S, Ye Z, Jaffar J, Zhou Y, Cutter E, Lieber A, Hellström I, Hellström KE.

Cancer Res. 2007 Mar 1;67(5):2339-44.

32.

MESOMARK: a potential test for malignant pleural mesothelioma.

Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY.

Clin Chem. 2007 Apr;53(4):666-72. Epub 2007 Feb 8.

33.

Mesothelin variant 1 is released from tumor cells as a diagnostic marker.

Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KE.

Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1014-20.

35.
36.

Impaired verb fluency: a sign of mild cognitive impairment.

Ostberg P, Fernaeus SE, Hellström K, Bogdanović N, Wahlund LO.

Brain Lang. 2005 Nov;95(2):273-9.

PMID:
16246735
37.

Soluble mesothelin-related protein--a blood test for mesothelioma.

Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I.

Lung Cancer. 2005 Jul;49 Suppl 1:S109-11.

PMID:
15950789
38.

Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.

Henry CJ, Buss MS, Hellström I, Hellström KE, Brewer WG, Bryan JN, Siegall CB.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):751-5.

39.

Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I.

Gynecol Oncol. 2004 Oct;95(1):9-15.

40.

Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas.

Malins DC, Gilman NK, Green VM, Wheeler TM, Barker EA, Vinson MA, Sayeeduddin M, Hellström KE, Anderson KM.

Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11428-31. Epub 2004 Jul 27.

41.

Development of a cancer DNA phenotype prior to tumor formation.

Malins DC, Anderson KM, Gilman NK, Green VM, Barker EA, Hellström KE.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10721-5. Epub 2004 Jul 12.

42.

Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.

Yang S, Yang Y, Raycraft J, Zhang H, Kanan S, Guo Y, Ronai Z, Hellstrom I, Hellstrom KE.

Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4990-5. Epub 2004 Mar 29.

43.

Novel approaches to therapeutic cancer vaccines.

Hellstrom KE, Hellstrom I.

Expert Rev Vaccines. 2003 Aug;2(4):517-32. Review.

PMID:
14711336
44.

Mesothelin-family proteins and diagnosis of mesothelioma.

Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I.

Lancet. 2003 Nov 15;362(9396):1612-6.

PMID:
14630441
45.

Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.

Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellström KE, Hellström I.

Mol Cancer Ther. 2003 Oct;2(10):995-1002.

46.

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE.

Cancer Res. 2003 Jul 1;63(13):3695-700.

47.

Therapeutic vaccination with tumor cells that engage CD137.

Hellstrom KE, Hellstrom I.

J Mol Med (Berl). 2003 Feb;81(2):71-86. Epub 2003 Feb 8. Review.

PMID:
12601523
48.

Antioxidant-induced changes in oxidized DNA.

Malins DC, Hellstrom KE, Anderson KM, Johnson PM, Vinson MA.

Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5937-41. Epub 2002 Apr 23.

49.

Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.

Ye Z, Hellström I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellström KE.

Nat Med. 2002 Apr;8(4):343-8.

PMID:
11927939
50.

Cutting edge: CD83 regulates the development of cellular immunity.

Scholler N, Hayden-Ledbetter M, Dahlin A, Hellström I, Hellström KE, Ledbetter JA.

J Immunol. 2002 Mar 15;168(6):2599-602.

Supplemental Content

Loading ...
Support Center